The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Conclusion: The adoption of the SC formulation for rituximab and trastuzumab can generate a greater "value" for both the national healthcare system and the patient compared to an IV formulation.
PMID: 32403958 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Health Management | Hematology | HER2 | Herceptin | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan | Study